News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Medical Announces Schedule of Programs for TCT 2012



10/17/2012 9:33:51 AM

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will release three-year clinical follow-up data on its CE Mark-approved DESyne® Novolimus Eluting Coronary Stent System, and one year clinical and MSCT (Multi Slice Computed Tomography) results for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the 24th annual Transcatheter Cardiovascular Technologies Conference in Miami on Tuesday, October 23.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES